Progetti

- Targeting fatty acid uptake pathway to revert resistance to anti-HER2 agents in HER2-positive breast cancer. PI S. Pupa, AIRC Call 2019 IG, 2020-2024
- miR-302b/BRCA regulatory loop as a tool to predict and promote PARPi-induced synthetic lethality. PI M.V. Iorio, AIRC Call 2020 IG, 2021-2025
- miR-9 inhibition as a strategy to disrupt tumor-MDSC communication. PI M.V. Iorio, Institutional funds (Research Line 2), 2024-2025
- Biomarkers for early diagnosis of breast cancer. PI M.V. Iorio, Institutional funds (Research Line 1), 2022-2024
- New potential therapeutic targets for triple negative breast cancer patients from the study of tumoradipocyte crosstalk. PI T. Triulzi, AIRC Call 2020 IG, 2021-2025
- Dissecting molecular mechanisms leading to drug resistance in breast carcinoma. PI T. Triulzi, Institutional funds (Research Line 2), 2023-2024
- Targeting pulmonary microbiota by aerosol: a new strategy to hit tumor cells in the lung. PI L. Sfondrini, AIRC Call 2020 IG, 2021-2025
- The evil trio: S. epidermidis, Tregs and macrophages cross-talk in promoting immunosuppression in breast cancer. PI L. Sfondrini, co-PI M. Sommariva, Institutional funds (Research Line 2), 2024-2025
- Window-of-opportunity umbrella trial as a translational platform for short-course pre-operative targeted treatments in non-metastatic resectable colorectal cancer: the UNICORN study. PI F. Pietrantonio, co-PI L. Castagnoli, Institutional funds (BRI), 2022-2025
- Role of gut miCrobiotA in the Recurrence of HER2-positive breaSt cancer (CARES). PI M. Di Modica, Berlucchi mini-Grant for young investigator 2022, 2023-2024